Marschner P, Ringwald K, Thill M, Zahn MO, et al. Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry. Int J Cancer 2026 Mar 18. doi: 10.1002/ijc.70433.
PMID: 41851017